Publications by authors named "Chandra Miduturu"
Dengue virus infects more than 300 million people annually, yet there is no widely protective vaccine or drugs against the virus. Efforts to develop antivirals against classical targets such as the viral protease and polymerase have not yielded drugs that have advanced to the clinic. Here, we show that the allosteric Abl kinase inhibitor GNF-2 interferes with dengue virus replication via activity mediated by cellular Abl kinases but additionally blocks viral entry via an Abl-independent mechanism.
View Article and Find Full Text PDFArticle Synopsis
- Aberrant signaling of the FGF19/FGFR4 complex is linked to hepatocellular carcinoma (HCC) in both mice and potentially humans, prompting the development of a targeted therapy.
- BLU9931 is a selective and irreversible small-molecule inhibitor specifically targeting FGFR4, showing strong anti-tumor effects in HCC models with overexpressed FGF19.
- About one-third of HCC patients with FGF19, FGFR4, and its coreceptor KLB may benefit from BLU9931 treatment, marking a significant advancement in targeted therapy for this cancer type.
The c-Fes protein-tyrosine kinase modulates cellular signaling pathways governing differentiation, the innate immune response, and vasculogenesis. Here, we report the identification of types I and II kinase inhibitors with potent activity against c-Fes both in vitro and in cell-based assays. One of the most potent inhibitors is the previously described anaplastic lymphoma kinase inhibitor TAE684.
View Article and Find Full Text PDF